All In Biotech

Drug Trial Radar · NCT02337062

Phase IIIb Study of APD421 in Combination as PONV Prophylaxis

Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Combination Prophylaxis Against Post-operative Nausea and Vomiting in High-risk Patients

Last checked: Nov 20, 2026Latest source record: Mar 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,147 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,147

Actual

Start

Feb 2015

Primary completion

Sep 2015

Study completion Sep 2015

Sponsor

Lead sponsor
Acacia Pharma LtdIndustry
Sponsor type
Industry
First posted
Jan 13, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A comparison of the efficacy of APD421 and placebo when combined with a standard anti-emetic in the prevention of PONV in patients at high risk of Post-operative Nausea and Vomiting (PONV).

Conditions

  • PONV

Interventions

  • APD421Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Complete ResponseTime frame: 24 hours after the end of surgery

Locations

25 sites in 3 countries. Site status is shown where the registry gives one.

  • Helen Keller Hospital

    Sheffield, Alabama

  • UCSF School of Medicine

    San Francisco, California

  • Jackson Memorial Hospital

    Miami, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Albany Medical Center Hospital

    Albany, New York

  • Stony Brook Medicine

    Stony Brook, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Wake Forest University School of Medicine

    Winston-Salem, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • First Street Surgical Center

    Bellaire, Texas

  • Victory Medical Center Houston

    Houston, Texas

  • Memorial Hermann-Memorial City Hospital

    Houston, Texas

  • University Hospital

    Besançon, France

  • Centre Hospitalier Lyon-Sud

    Lyon, France

  • Centre Hospitalier de Mulhouse

    Mulhouse, France

  • Hopital Foch

    Paris, France

  • CHU de Hautepierre

    Strasbourg, France

  • HELIOS Klinikum Aue

    Aue, Germany

  • Universitätsklinikum Bonn

    Bonn, Germany

  • Klinikum Ludwigshafen

    Ludwigshafen, Germany

  • Universitätsmedizin Mainz

    Mainz, Germany

  • Philipps University

    Marburg, Germany

  • University Hospitals of Würzburg

    Würzburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.